The drug should be discontinued if patients develop ALT of ≥5x ULN or ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR (international normalized ratio). Here, GPT is linked to inflammatory response.